1
Country: USA | Funding: $203.1M
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
2
Country: USA | Funding: $110.3M
Crossbow Therapeutics develops antibody therapeutics to treat cancer. It identifies, validates and prioritizes the most promising cancer antigens for its T-Cell Receptor mimetic (TCRm) discovery efforts. Its lead candidate is T-cell engager CBX-250, designed to target a peptide human leukocyte antigen (pHLA) that’s found on myeloid cancer cells. The company is conducting trials which have enrolled patients with acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia. Crossbow also develops other so-called T-Bolt immunotherapies, which use TCR-mimetic antibodies to target pHLA on cancer cells.
Crossbow Therapeutics develops antibody therapeutics to treat cancer. It identifies, validates and prioritizes the most promising cancer antigens for its T-Cell Receptor mimetic (TCRm) discovery efforts. Its lead candidate is T-cell engager CBX-250, designed to target a peptide human leukocyte antigen (pHLA) that’s found on myeloid cancer cells. The company is conducting trials which have enrolled patients with acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia. Crossbow also develops other so-called T-Bolt immunotherapies, which use TCR-mimetic antibodies to target pHLA on cancer cells.
3
Country: USA | Funding: $112.5M
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
4
Country: France | Funding: €135M
Adcytherix is dedicated to creating and advancing innovative antibody-drug conjugates (ADCs) that go beyond current limitations. By combining state-of-the-art payload innovation with deep ADC development expertise, the company aims to revolutionize targeted therapies for cancer and other conditions of significant unmet medical need. Most existing ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors. Adcytherix is investigating novel payloads classes with mechanisms of action selected to overcome tumor resistance while enhancing safety, with the potential to manage a wider range of cancers. Adcytherix is guided by a experienced management team and is backed by a network of top-tier experts in the field of ADC development.
Adcytherix is dedicated to creating and advancing innovative antibody-drug conjugates (ADCs) that go beyond current limitations. By combining state-of-the-art payload innovation with deep ADC development expertise, the company aims to revolutionize targeted therapies for cancer and other conditions of significant unmet medical need. Most existing ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors. Adcytherix is investigating novel payloads classes with mechanisms of action selected to overcome tumor resistance while enhancing safety, with the potential to manage a wider range of cancers. Adcytherix is guided by a experienced management team and is backed by a network of top-tier experts in the field of ADC development.
5
Country: USA | Funding: $414.8M
Abcuro develops immunotherapeutics for the treatment of autoimmune diseases and cancer. Its flagship antibody-drug Ulviprubart targets the selective elimination of highly cytotoxic T cells expressing KLRG1 while sparing key lymphocyte populations, including naive, memory, and regulatory T cells, which are essential for maintaining normal immune homeostasis. Ulviprubart is in clinical trials for the treatment of highly cytotoxic T cell-mediated diseases, including the autoimmune muscle disease inclusion body myositis, T-cell large granular lymphocytic leukemia and mature T-cell malignancies.
Abcuro develops immunotherapeutics for the treatment of autoimmune diseases and cancer. Its flagship antibody-drug Ulviprubart targets the selective elimination of highly cytotoxic T cells expressing KLRG1 while sparing key lymphocyte populations, including naive, memory, and regulatory T cells, which are essential for maintaining normal immune homeostasis. Ulviprubart is in clinical trials for the treatment of highly cytotoxic T cell-mediated diseases, including the autoimmune muscle disease inclusion body myositis, T-cell large granular lymphocytic leukemia and mature T-cell malignancies.
6
Country: USA | Funding: $315M
Star Therapeutics mission is to develop therapies for people living with serious bleeding disorders and other diseases in hematology and immunology
Star Therapeutics mission is to develop therapies for people living with serious bleeding disorders and other diseases in hematology and immunology
7
Country: USA | Funding: $283M
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
8
Country: USA | Funding: $253M
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
9
Country: Singapore | Funding: $187M
Callio Therapeutics develops next-generation antibody-drug conjugates (ADCs) with multiple payloads. They feature differentiated payload and linker technologies, which enables targeted delivery of drug combinations to tumor cells to maximize therapeutic effects for cancer patients. The company's flagship program is an ADC targeting HER2 breast cancer. Callio is a spinoff of Singapore-based Hummingbird Bioscience, which shares the CEO with Callio.
Callio Therapeutics develops next-generation antibody-drug conjugates (ADCs) with multiple payloads. They feature differentiated payload and linker technologies, which enables targeted delivery of drug combinations to tumor cells to maximize therapeutic effects for cancer patients. The company's flagship program is an ADC targeting HER2 breast cancer. Callio is a spinoff of Singapore-based Hummingbird Bioscience, which shares the CEO with Callio.
10
Country: USA | Funding: $165M
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.
11
Country: USA | Funding: $99.3M
BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
12
Country: USA | Funding: $86.9M
Vaccinex develops novel therapeutic antibodies for treatment of neurodegenerative diseases and cancer. Its drugs are based on the inhibition of semaphorin SEMA4D - potent biological effector believed to prevent immune infiltration and induce myeloid-derived suppressor cells in tumors, as well as trigger neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has the potential to enhance immune activity against tumors and reprogram underlying pathogenic immune mechanisms that exacerbate damage in chronic neurological diseases such as Asheimer's disease and Huntington's disease. The company is also advancing candidates for the treatment of cervical, pancreatic and lung cancer. Vaccinex uses its proprietary ActivMAb drug discovery platform, which enables the discovery and development of highly selective antibodies with novel mechanisms of action against complex membrane proteins.
Vaccinex develops novel therapeutic antibodies for treatment of neurodegenerative diseases and cancer. Its drugs are based on the inhibition of semaphorin SEMA4D - potent biological effector believed to prevent immune infiltration and induce myeloid-derived suppressor cells in tumors, as well as trigger neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has the potential to enhance immune activity against tumors and reprogram underlying pathogenic immune mechanisms that exacerbate damage in chronic neurological diseases such as Asheimer's disease and Huntington's disease. The company is also advancing candidates for the treatment of cervical, pancreatic and lung cancer. Vaccinex uses its proprietary ActivMAb drug discovery platform, which enables the discovery and development of highly selective antibodies with novel mechanisms of action against complex membrane proteins.
13
Country: USA | Funding: $75M
Neok is a spin-off of Korean biotech ABL, that paired its antibody skills with linker-payload technology to build a pipeline of ADCs. Neok was started with two ADC-candidates from ABL and plans to test them and deliver the first human data in 2027. The drugs target thoracic, gastrointestinal and gynecological cancers via ROR1, EGFR and MUC1 proteins. The expression of these proteins by some healthy cells makes on-target, off-tumor toxicity a concern for drugs that engage the receptor. But, in theory, Neok's bispecific design (which is fine-tuned for each target antigen pair) could improve safety. This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance.
Neok is a spin-off of Korean biotech ABL, that paired its antibody skills with linker-payload technology to build a pipeline of ADCs. Neok was started with two ADC-candidates from ABL and plans to test them and deliver the first human data in 2027. The drugs target thoracic, gastrointestinal and gynecological cancers via ROR1, EGFR and MUC1 proteins. The expression of these proteins by some healthy cells makes on-target, off-tumor toxicity a concern for drugs that engage the receptor. But, in theory, Neok's bispecific design (which is fine-tuned for each target antigen pair) could improve safety. This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance.
14
Country: USA
AAA Biotech (also known as AAA Bio or AAABio) is constantly working to expand its capacity to provide antibodies, recombinant proteins and ELISA kits targeting a wide range of proteins. The majority of AAA Biotech’s antibodies are highly validated and can be use in multiple applications such as ELISA, FC, ICC, IF, IHC, IP, WB, etc. The company has antibodies available for rare species, in multiple conjugated forms or recombinant antibodies.
AAA Biotech (also known as AAA Bio or AAABio) is constantly working to expand its capacity to provide antibodies, recombinant proteins and ELISA kits targeting a wide range of proteins. The majority of AAA Biotech’s antibodies are highly validated and can be use in multiple applications such as ELISA, FC, ICC, IF, IHC, IP, WB, etc. The company has antibodies available for rare species, in multiple conjugated forms or recombinant antibodies.
